refractory/relapsed and elderly acute myeloid leukemia
Conditions
Interventions
Test Group:thalidomide,interferon,interleukin-2
Sponsors
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) 18 to 80 years of age; (2)male and female; (3)diagnosed refractory/relapsed and elderly acute myeloid leukemia (>60 years old) and exclude APL; (4)no limit to previous therapy(5)cardiac function NYHA class45%,antharcyclines cumulative dose less than 240mg/m2 (6) STB=1.5×institutional upper limit of normal (ULN),ALT, AST=2.5×ULN (7) BUN,SCr?2.5×ULN (8) without other malignancy,or severe infection; (9) ECOG performance status ?2; (10) expected survival time>3 months; (11) signed informed consent.
Exclusion criteria
Exclusion criteria: (1) not diagnosed refractory/relapsed and elderly acute myeloid leukemia; (2)serious allergy to thalidomide,interferon or interleukin-2 with clinical manifestation of anaphylactic shock and laryngeal edema; (3) pregnancy or nursing; (4) suffered with malignancy in addition to NHL,severe infection or central nervous system AML; (5) have significant heart disease activity within the previous 6 months:MI,class ?-? congestive heart failure according to NYHA,unstable ungina,unstable pericardiac disease and cardiac amyloidosis; (6) ?2 peripheral neuropathy according to NCTCTCAE 4.0; (7) ALT,AST?2.5×ULN,STB?1.5×ULN; (8) lung function decompensation; (9) renal failure; (10) psychotic episodes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate;complete remission;part remissio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress-free survival;overall surviva; | — |
Contacts
Public ContactWei XuDong
Outcome results
None listed